-
Je něco špatně v tomto záznamu ?
Cytogenetics in Chronic Lymphocytic Leukemia: ERIC Perspectives and Recommendations
P. Baliakas, B. Espinet, C. Mellink, M. Jarosova, A. Athanasiadou, P. Ghia, AP. Kater, D. Oscier, C. Haferlach, K. Stamatopoulos
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
PubMed Central od 2017
Europe PubMed Central od 2017
Wiley-Blackwell Open Access Titles od 1997
Odkazy
PubMed
35392482
DOI
10.1097/hs9.0000000000000707
Knihovny.cz E-zdroje
- Publikační typ
- časopisecké články MeSH
Mounting evidence underscores the clinical value of cytogenetic analysis in chronic lymphocytic leukemia (CLL), particularly as it allows the identification of complex karyotype, that has recently emerged as a prognostic and potentially predictive biomarker. That said, explicit recommendations regarding the methodology and clinical interpretation of either chromosome banding analysis (CBA) or chromosome microarray analysis (CMA) are still lacking. We herein present the consensus of the Cytogenetic Steering Scientific Committee of ERIC, the European Research Initiative on CLL, regarding methodological issues as well as clinical interpretation of CBA/CMA and discuss their relevance in CLL. ERIC considers CBA standardized and feasible for CLL on the condition that standards are met, extending from the use of novel mitogens to the accurate interpretation of the findings. On the other hand, CMA, is also standardized, however, robust data on its clinical utility are still scarce. In conclusion, cytogenetic analysis is not yet mature enough to guide treatment choices in CLL. That notwithstanding, ERIC encourages the wide application of CBA, and potentially also CMA, in clinical trials in order to obtain robust evidence regarding the predictive value of specific cytogenetic profiles towards refining risk stratification and improving the management of patients with CLL.
Department of Clinical Genetics Uppsala University Hospital Sweden
Department of Haematology Royal Bournemouth Hospital United Kingdom
Department of Molecular Medicine and Surgery Karolinska Institutet Stockholm Sweden
Hematology Department and HCT Unit G Papanicolaou Hospital Thessaloniki Greece
Institute of Applied Biosciences Center for Research and Technology Hellas Thessaloniki Greece
MLL Munich Leukemia Laboratory Munich Germany
Molecular Cytogenetics Laboratory Pathology Department Hospital del Mar Barcelona Spain
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22017524
- 003
- CZ-PrNML
- 005
- 20220720100250.0
- 007
- ta
- 008
- 220718s2022 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1097/HS9.0000000000000707 $2 doi
- 035 __
- $a (PubMed)35392482
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Baliakas, Panagiotis $u Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Sweden $u Department of Clinical Genetics, Uppsala University Hospital, Sweden
- 245 10
- $a Cytogenetics in Chronic Lymphocytic Leukemia: ERIC Perspectives and Recommendations / $c P. Baliakas, B. Espinet, C. Mellink, M. Jarosova, A. Athanasiadou, P. Ghia, AP. Kater, D. Oscier, C. Haferlach, K. Stamatopoulos
- 520 9_
- $a Mounting evidence underscores the clinical value of cytogenetic analysis in chronic lymphocytic leukemia (CLL), particularly as it allows the identification of complex karyotype, that has recently emerged as a prognostic and potentially predictive biomarker. That said, explicit recommendations regarding the methodology and clinical interpretation of either chromosome banding analysis (CBA) or chromosome microarray analysis (CMA) are still lacking. We herein present the consensus of the Cytogenetic Steering Scientific Committee of ERIC, the European Research Initiative on CLL, regarding methodological issues as well as clinical interpretation of CBA/CMA and discuss their relevance in CLL. ERIC considers CBA standardized and feasible for CLL on the condition that standards are met, extending from the use of novel mitogens to the accurate interpretation of the findings. On the other hand, CMA, is also standardized, however, robust data on its clinical utility are still scarce. In conclusion, cytogenetic analysis is not yet mature enough to guide treatment choices in CLL. That notwithstanding, ERIC encourages the wide application of CBA, and potentially also CMA, in clinical trials in order to obtain robust evidence regarding the predictive value of specific cytogenetic profiles towards refining risk stratification and improving the management of patients with CLL.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Espinet, Blanca $u Molecular Cytogenetics Laboratory, Pathology Department, Hospital del Mar, Barcelona, Spain $u Translational Research on Hematological Neoplasms Group, Cancer Research Program, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain
- 700 1_
- $a Mellink, Clemens $u Genomics Laboratory, Department of Clinical Genetics, Amsterdam University Medical Centers, University of Amsterdam, the Netherlands
- 700 1_
- $a Jarosova, Marie $u Institute of Medical Genetics and Genomics, Faculty of Medicine, Masaryk University and University Hospital Brno, Czech Republic $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Athanasiadou, Anastasia $u Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece
- 700 1_
- $a Ghia, Paolo $u Strategic Research Program in CLL and BCell Neoplasia Unit, Division of Experimental Oncology, IRCCS Ospedale San Raffaele and Università Vita-Salute San Raffaele, Milan, Italy
- 700 1_
- $a Kater, Arnon P $u Department of Hematology, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, the Netherlands
- 700 1_
- $a Oscier, David $u Department of Haematology, Royal Bournemouth Hospital, United Kingdom
- 700 1_
- $a Haferlach, Claudia $u MLL Munich Leukemia Laboratory, Munich, Germany
- 700 1_
- $a Stamatopoulos, Kostas $u Institute of Applied Biosciences, Center for Research and Technology Hellas, Thessaloniki, Greece $u Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
- 773 0_
- $w MED00201259 $t HemaSphere $x 2572-9241 $g Roč. 6, č. 4 (2022), s. e707
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35392482 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20220718 $b ABA008
- 991 __
- $a 20220720100245 $b ABA008
- 999 __
- $a ind $b bmc $g 1816631 $s 1168766
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 6 $c 4 $d e707 $e 20220325 $i 2572-9241 $m HemaSphere $n Hemasphere $x MED00201259
- LZP __
- $a Pubmed-20220718
